Long non‐coding RNA as a novel biomarker and therapeutic target in aggressive B‐cell non‐Hodgkin lymphoma: A systematic review

Cancer initiation and progression have been associated with dysregulated long non‐coding RNA (lncRNA) expression. However, the lncRNA expression profile in aggressive B‐cell non‐Hodgkin lymphoma (NHL) has not been comprehensively characterized. This systematic review aims to evaluate the role of lnc...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of cellular and molecular medicine Ročník 27; číslo 14; s. 1928 - 1946
Hlavní autoři: Khanmohammadi, Shaghayegh, Fallahtafti, Parisa
Médium: Journal Article
Jazyk:angličtina
Vydáno: England John Wiley & Sons, Inc 01.07.2023
John Wiley and Sons Inc
Témata:
Adult
aggressive non‐Hodgkin lymphoma
Apoptosis
B-cell lymphoma
biomarker
Biomarkers
Burkitt Lymphoma - drug therapy
Burkitt's lymphoma
Cell cycle
Cell migration
Cell proliferation
Chemotherapy
Cyclin-dependent kinases
Diagnosis
diffuse large B‐cell lymphoma
Epigenetics
Growth factors
Humans
Kinases
Leukemia
long non‐coding RNA
Lymphocytes
Lymphocytes B
Lymphoma
Lymphoma, Large B-Cell, Diffuse - diagnosis
Lymphoma, Large B-Cell, Diffuse - drug therapy
Lymphoma, Large B-Cell, Diffuse - genetics
Lymphoma, Mantle-Cell
Mantle cell lymphoma
Non-coding RNA
Non-Hodgkin's lymphoma
non‐Hodgkin lymphomas
Pathogenesis
Prognosis
Proteins
Review
Reviews
RNA, Long Noncoding - genetics
Systematic review
Therapeutic applications
Therapeutic targets
non-Hodgkin lymphomas
aggressive non-Hodgkin lymphoma
mantle cell lymphoma
long non-coding RNA
diffuse large B-cell lymphoma
biomarker
Burkitt's lymphoma
ISSN:1582-1838, 1582-4934, 1582-4934
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Cancer initiation and progression have been associated with dysregulated long non‐coding RNA (lncRNA) expression. However, the lncRNA expression profile in aggressive B‐cell non‐Hodgkin lymphoma (NHL) has not been comprehensively characterized. This systematic review aims to evaluate the role of lncRNAs as a biomarker to investigate their future potential in the diagnosis, real‐time measurement of response to therapy and prognosis in aggressive B‐cell NHL. We searched PubMed, Web of Science, Embase and Scopus databases using the keywords “long non‐coding RNA”, “Diffuse large B‐cell lymphoma”, “Burkitt's lymphoma” and “Mantle cell lymphoma”. We included studies on human subjects that measured the level of lncRNAs in samples from patients with aggressive B‐cell NHL. We screened 608 papers, and 51 papers were included. The most studied aggressive B‐cell NHL was diffuse large B‐cell lymphoma (DLBCL). At least 79 lncRNAs were involved in the pathogenesis of aggressive B‐cell NHL. Targeting lncRNAs could affect cell proliferation, viability, apoptosis, migration and invasion in aggressive B‐cell NHL cell lines. Dysregulation of lncRNAs had prognostic (e.g. overall survival) and diagnostic values in patients with DLBCL, Burkitt's lymphoma (BL), or mantle cell lymphoma (MCL). Furthermore, dysregulation of lncRNAs was associated with response to treatments, such as CHOP‐like chemotherapy regimens, in these patients. LncRNAs could be promising biomarkers for the diagnosis, prognosis and response to therapy in patients with aggressive B‐cell NHL. Additionally, lncRNAs could be potential therapeutic targets for patients with aggressive B‐cell NHL like DLBCL, MCL or BL.
Bibliografie:Shaghayegh Khanmohammadi and Parisa Fallahtafti contributed equally to this work.
ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Undefined-1
ObjectType-Review-4
content type line 23
ISSN:1582-1838
1582-4934
1582-4934
DOI:10.1111/jcmm.17795